7.55
  Price0.67%   +0.0500
(After Hours: 7.99 +0.44 +5.83%)
Mar-29-21 07:00AM Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood DisordersGlobeNewswire
Mar-22-21 04:05AM SHAREHOLDER ALERT: Investigation of IMARA Inc. Announced by Holzer & Holzer, LLCNewsfile
Mar-17-21 07:00AM Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-ThalassemiaGlobeNewswire
Mar-15-21 11:00AM Bronstein, Gewirtz & Grossman, LLC Announces Investigation of IMARA, Inc. (IMRA) and Encourages Investors to Contact the FirmACCESSWIRE
Mar-14-21 08:16AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRANewsfile
Mar-12-21 05:45AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRACNW Group
Mar-10-21 02:40AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRACNW Group
Mar-05-21 07:00AM Imara Reports Full Year 2020 Financial Results and Business HighlightsGlobeNewswire
06:30AM Imara Inc to Host Earnings CallACCESSWIRE
Feb-26-21 09:30AM Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business HighlightsGlobeNewswire
Feb-19-21 07:00AM Imara to Present at SVB Leerink 10th Annual Global Healthcare ConferenceGlobeNewswire
Jan-20-21 07:00AM Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical OfficerGlobeNewswire
Jan-06-21 05:21AM Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data ReadoutsBenzinga
07:00AM Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell DiseaseGlobeNewswire
Dec-10-20 01:01AM We Think IMARA (NASDAQ:IMRA) Can Afford To Drive Business GrowthSimply Wall St.
Dec-07-20 07:00AM Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and ExpositionGlobeNewswire
Nov-30-20 10:36AM Do Hedge Funds Love IMARA Inc. (IMRA)?Insider Monkey
07:00AM Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and ExpositionGlobeNewswire
Nov-17-20 07:00AM Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of RegulatoryGlobeNewswire
Nov-05-20 07:00AM Imara Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewswire
Oct-31-20 08:00AM Kaskela Law LLC Announces Stockholder Investigation of Imara Inc. - IMRAACCESSWIRE
Oct-29-20 07:00AM Imara to Webcast Conference Call of Third Quarter Financial ResultsGlobeNewswire
Oct-16-20 07:00AM Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-ThalassemiaGlobeNewswire
Sep-02-20 07:00AM Imara to Present at Upcoming Investor ConferencesGlobeNewswire
Aug-25-20 07:00AM Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell DiseaseGlobeNewswire
Aug-14-20 07:00AM Imara Reports Second Quarter 2020 Financial Results and Business HighlightsGlobeNewswire
Aug-13-20 04:01AM Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell DiseaseGlobeNewswire
Aug-07-20 07:00AM Imara to Webcast Conference Call of Second Quarter 2020 Financial ResultsGlobeNewswire
Jul-30-20 07:00AM Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-ThalassemiaGlobeNewswire
Jun-29-20 04:01AM Imara Added to Membership of U.S. Small-Cap Russell 2000® IndexGlobeNewswire
Jun-25-20 07:00AM Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood DisordersGlobeNewswire
Jun-24-20 07:00AM Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemiaGlobeNewswire
Jun-22-20 01:57AM Here is What Hedge Funds Think About IMARA Inc. (IMRA)Insider Monkey
Jun-13-20 08:44AM Here's Why We're Not Too Worried About IMARA's (NASDAQ:IMRA) Cash Burn SituationSimply Wall St.
Jun-12-20 07:00AM Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual CongressGlobeNewswire
May-21-20 07:00AM Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) CongressGlobeNewswire
May-07-20 07:00AM Imara Reports First Quarter 2020 Financial Results and Business HighlightsGlobeNewswire
May-06-20 07:00AM Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood DisordersGlobeNewswire
May-04-20 07:00AM Imara Announces Appointment of Stephen M. Migausky as General CounselGlobeNewswire
Apr-23-20 07:00AM Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.GlobeNewswire
Mar-11-20 09:57AM IMARA Announces Pricing of Initial Public OfferingGlobeNewswire
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Cap:    |  Volume (24h):